Robert T. Streeper is a notable inventor based in San Antonio, TX (US). He has made significant contributions to the field of pharmaceuticals, particularly in the treatment of insulin resistance and diseases associated with phospholipase D toxin. With a total of 10 patents to his name, Streeper's work has the potential to impact many lives.

Latest Patents

One of Streeper's latest patents is titled "Azelaic acid esters in the treatment of insulin resistance." This patent describes a method of treating insulin resistance by administering a pharmaceutical composition that includes diethyl azelate. The method suggests an oral dosage range from about 0.1 mg/kg/day to about 10 mg/kg/day. Another significant patent is focused on "Dicarboxylic acid esters for the treatment of diseases and conditions associated with phospholipase D toxin." This disclosure provides compositions and methods for treating diseases linked to phospholipase D (PLD) toxin, emphasizing the administration of a dicarboxylic acid ester to subjects in need.

Career Highlights

Throughout his career, Streeper has worked with various organizations, including Cancer Prevention and Cure, Ltd. and New Frontier Labs, LLC. His innovative approaches and research have positioned him as a key figure in the pharmaceutical industry.

Collaborations

Streeper has collaborated with notable professionals in his field, including Elzbieta Izbicka and Sung H. Baek. These partnerships have likely contributed to the advancement of his research and the successful development of his patents.

Conclusion

Robert T. Streeper's contributions to pharmaceutical innovations demonstrate his commitment to improving health outcomes. His patents reflect a deep understanding of complex medical issues and a dedication to finding effective treatments.

This text is generated by artificial intelligence and may not be accurate.